Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: A randomized controlled trial

JAMA

Volumn 291, Issue 21, 2004, Pages 2555-2562

  Kaul, Rupert ^a,b,d,e   Kimani, Joshua ^b   Nagelkerke, Nico J ^g,h   Fonck, Karoline ^b,i   Ngugi, Elizabeth N ^c   Keli, Florence ^b   MacDonald, Kelly S ^d,f   Maclean, Ian W ^h   Bwayo, Job J ^b   Temmerman, Marleen ⁱ   Ronald, Allan R ^h   Moses, Stephen ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; CONDOM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIRECTLY OBSERVED THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; GENITAL HERPES; HAEMOPHILUS DUCREYI; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; KENYA; MAJOR CLINICAL STUDY; NEISSERIA GONORRHOEAE; PATIENT COUNSELING; POVERTY; PREVALENCE; PRIORITY JOURNAL; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEROPREVALENCE; SEXUALLY TRANSMITTED DISEASE; STOMACH ACID SECRETION; STOMACH HYPERACIDITY; TREPONEMA PALLIDUM; TRICHOMONAS VAGINALIS; URBAN AREA; VAGINITIS; VOMITING; RISK FACTOR; STATISTICS;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DOUBLE-BLIND METHOD; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; KENYA; PREVALENCE; PROSTITUTION; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES, BACTERIAL;

EID: 2542489200     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.21.2555     Document Type: Article

References (32)

1. Cohen MS, Hoffman IF, Royce RA, et al, AIDSCAP Malawi Research Group. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet. 1997;349:1868-1873.
2. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS. 1997;11:F85-F93.
3. Corbett EL, Steketee RW, ter Kuile FO, Latif AS, Kamali A, Hayes RJ. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet. 2002;359: 2177-2187.
4. Kaul R, Kimani J, Nagelkerke NJ, et al. Risk factors for genital ulcerations in Kenyan sex workers: the role of human immunodeficiency virus type 1 infection. Sex Transm Dis. 1997;24:387-392.
5. Cameron DW, Simonsen JN, D'Costa U, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet. 1989;2:403-407.
6. Plummer FA, Simonsen JN, Cameron DW, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1991; 163:233-239.
7. Cohen MS, Miller WC. Sexually transmitted diseases and human immunodeficiency virus infection: cause, effect, or both? Int J Infect Dis. 1998;3:1-4.
8. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346:530-536.
9. Wawer MJ, Sewankambo NK, Serwadda D, et al, Rakai Project Study Group. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Lancet. 1999;353:525-535.
10. Kamali A, Quigley M, Nakiyingi J, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet. 2003;361:645-652.
11. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet. 2000;355:1981-1987.
12. Hudson CP. Community-based trials of sexually transmitted disease treatment: repercussions for epidemiology and HIV prevention. Bull World Health Organ. 2001;79:48-58.
13. Stephenson J, Cowan F. Evaluating interventions for HIV prevention in Africa. Lancet. 2003;361: 633-634.
14. Gray RH, Wawer MJ, Sewankambo NK, et al, Rakai Project Team. Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. AIDS. 1999;13:2113-2123.
15. Plummer FA, Nagelkerke NJ, Moses S, Ndinya-Achola JO, Bwayo J, Ngugi E. The importance of core groups in the epidemiology and control of HIV-1 infection. AIDS. 1991;5(suppl 1):S169-S176.
16. Boily MC, Lowndes CM, Alary M. Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda. AIDS. 2000;14:2583-2592.
17. Alary M. More community-based trials of STD control or more appropriate interventions: which is the priority for preventing HIV-1 infection in developing countries? Bull World Health Organ. 2001;79:59-60.
18. Simonsen JN, Plummer FA, Ngugi EN, et al. HIV infection among lower socioeconomic strata prostitutes in Nairobi. AIDS. 1990;4:139-144.
19. Martin HL Jr, Jackson DJ, Mandaliya K, et al. Preparation for AIDS vaccine evaluation in Mombasa, Kenya: establishment of seronegative cohorts of commercial sex workers and trucking company employees. AIDS Res Hum Retroviruses. 1994;10(suppl 2):S235-S237.
20. Ngugi EN, Wilson D, Sebstad J, Plummer FA, Moses S. Focused peer-mediated educational programs among female sex workers to reduce sexually transmitted disease and human immunodeficiency virus transmission in Kenya and Zimbabwe. J Infect Dis. 1996;174(suppl 2):S240-S247.
21. Abellanosa I, Nichter M. Antibiotic prophylaxis among commercial sex workers in Cebu City, Philippines: patterns of use and perceptions of efficacy. Sex Transm Dis. 1996;23:407-412.
22. Fonck K, Kaul R, Kimani J, et al. A randomized, placebo-controlled trial of monthly azithromycin prophylaxis to prevent sexually transmitted infections and HIV-1 in Kenyan sex workers: study design and baseline findings. Int J STD AIDS. 2000;11:804-811.
23. Lowndes CM, Alary M, Gnintoungbe CA, et al. Management of sexually transmitted diseases and HIV prevention in men at high risk: targeting clients and non-paying sexual partners of female sex workers in Benin. AIDS. 2000;14:2523-2534.
24. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
25. Kaul R, Kimani J, Nagelkerke NJ, et al. Reduced HIV risk-taking and low HIV incidence after enrollment and risk-reduction counseling in a sexually transmitted disease prevention trial in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2002;30:69-72.
26. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360:971-977.
27. Steen R, Vuylsteke B, DeCoito T, et al. Evidence of declining STD prevalence in a South African mining community following a core-group intervention. Sex Transm Dis. 2000;27:1-8.
28. Sutton MY. Lower genital tract infections and HIV in women. Curr Infect Dis Rep. 2000;2:539-545.
29. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis. 2003;187:1513-1521.
30. Wald A, Corey L. How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? J Infect Dis. 2003;187: 1509-1512.
31. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35:435-445.
32. Duran JM, Amsden GW. Azithromycin: indications for the future? Expert Opin Pharmacother. 2000; 1:489-505.